Evidence map›Paper›PMID 40005476›Full record

ArticleMedicina (Kaunas, Lithuania)2025

A Comparison of the Efficacy and Safety of Denosumab and Zoledronic Acid in Patients with Bone Metastatic Breast Cancer Receiving CDK4/6 Inhibitor Therapy.

İrem Öner, Hicran Anık, Bediz Kurt İnci, Pınar Kubilay Tolunay, Öztürk Ateş, Ülkü Yalçıntaş Arslan, Cengiz Karaçin

Abstract readComparative Study
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Mechanisms of breast cancer dormancy in bone metastasis.Clinical & experimental metastasis · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

İrem ÖnerDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.
Hicran AnıkDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.ORCID 0009-0001-7992-4008
Bediz Kurt İnciDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.
Pınar Kubilay TolunayDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.ORCID 0000-0003-2636-5326
Öztürk AteşDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.ORCID 0000-0003-0182-3933
Ülkü Yalçıntaş ArslanDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.
Cengiz KaraçinDepartmant of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, 06200 Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bone Density Conservation AgentsBone NeoplasmsBreast NeoplasmsDenosumabZoledronic AcidAdultAgedAminopyridinesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6FemaleHumansMiddle AgedPiperazinesPurinesPyridinesAminopyridinesBone Density Conservation AgentsCDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6DenosumabpalbociclibPiperazinesPurinesPyridinesribociclibZoledronic Acidbone metastasisbreast cancercdk4/6 inhibitordenosumabpalbociclibRANKL inhibitorribociclibskeletal-related eventzoledronic acid

Identifiers

PMID40005476
PMCPMC11857531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.